Search - tctmd.com

Displaying 21 - 37 of 37

Sort: Relevancy | Date

News Daily News

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Yael L. Maxwell

October 20, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Presentation

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

April 18, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2016

Shelley Wood

July 01, 2016

News Daily News

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Yael L. Maxwell

July 29, 2015

News Conference News ESC 2012

Stem Cells, Nanoparticles Appear to be an Antidote to Atherosclerosis

Caitlin E. Cox

August 29, 2012

Advertisement

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Boston Scientific Scraps Biodegradable Scaffold Program

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

TCTMD’s Top 10 Most Popular Stories for June 2016

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Stem Cells, Nanoparticles Appear to be an Antidote to Atherosclerosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content